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Abstract 
Introduction: Laparoscopic adjustable gastric band (LAGB) related complications have been 
reported in significant numbers of patients often leading to band removal. Increasingly 
revisional bariatric surgery (RBS) is offered, most commonly either band to roux-en-y gastric 
bypass (B-RYGB) or band to sleeve gastrectomy (B-SG).  
Objectives: We conducted a systematic review and meta-analysis of studies to evaluate the 
efficacy of RBS following failed LAGB. 
Methods Medline, Embase, The Cochrane Library and NHS Evidence were searched for 
English language studies assessing patients who had undergone LAGB and who subsequently 
underwent RBS (either B-RYGB or B-SG).   
Results: Thirty-six studies met the inclusion criteria. In total there were 2617 patients. B-
RYGB was performed in 60.5% (n=1583). There was only one death within 30 days reported 
(0.0004%). The overall pooled morbidity rate was 13.2%. There was no difference between 
the B-RYGB and B-SG groups in overall morbidity, leak rate or return to theatre. Percentage 
excess weight loss (%EWL) following the revisional procedure for all patients combined at 6, 
12 and 24 months was 44.5%, 55.7% and 59.7% respectively. There was no statistical 
difference in %EWL between B-RYGB and B-SG at any time point. The rates of remission 
of diabetes, hypertension and obstructive sleep apnoea were 46.5%, 35.9% and 80.8% 
respectively. 
Conclusions: Randomised controlled trials (RCTs) do not exist on this issue but the available 
observational evidence does suggest that RBS is associated with generally good outcomes 
similar to those experienced after primary surgery. Further, high quality research, particularly 
RCTs, is required to assess long-term weight loss, comorbidity and quality of life outcomes.  
Introduction 
The prevalence of obesity worldwide continues to grow and is a significant burden on 
individuals and healthcare systems. Bariatric surgery is the most effective treatment option 
that results in significant long term sustainable weight loss.{{593 Colquitt,J.L. 2014; 595 
Courcoulas,A.P. 2014; 594 Gloy,V.L. 2013}} The laparoscopic adjustable gastric band 
(LAGB) was the first bariatric procedure to gain widespread acceptance due to its good 
weight loss results in the short term, its relative simplicity and low early complication 
rates.{{599 Chapman,A.E. 2004}} However, randomised and non-randomised studies have 
shown that roux-en-y gastric bypass (RYGB) and sleeve gastrectomy (SG) are superior to 
LAGB in terms of weight loss and impact on obesity related comorbidities.{{601 Boza,C. 
2011; 605 Hutter,M.M. 2011; 600 Tice,J.A. 2008}} As a result there has been a significant 
fall worldwide in the number of LAGBs performed in favour of RYGB and SG.{{597 
Buchwald,H. 2013; 596 Buchwald,H. 2009; 598 Angrisani,L. 2015}} 
The rate of LAGB related complications such as band erosion, band slippage, oesophageal 
dilatation and dysmotility and tube or port dysfunction can be as high as 15-58% often 
leading to band removal.{{602 Gustavsson,S. 2002; 607 Lanthaler,M. 2010; 603 Suter,M. 
2006; 604 Spivak,H. 2012; 584 Weber,M. 2003}} In addition, a substantial proportion of 
patients fail to lose sufficient weight with LAGB alone;{{606 Biertho,L. 2005; 607 
Lanthaler,M. 2010}} in one study insufficient weight loss (defined as percentage excess 
weight loss (%EWL) of <25%) was reported in 10.5% of patients at 5 years.{{603 Suter,M. 
2006}} 
Increasingly therefore, revisional bariatric surgery (RBS) is being performed to remove the 
gastric band and convert to another bariatric procedure, most commonly RYGB or SG. 
Previous systematic reviews have demonstrated both the safety and efficacy of RBS.{{609 
Mahawar,K.K. 2015; 610 Cheung,D. 2014; 608 Elnahas,A. 2013}} Despite this, the efficacy 
of RBS in terms of weight loss might be inferior to primary bariatric surgery (PBS) and the 
complication rates higher.{{611 Zhang,L. 2015; 609 Mahawar,K.K. 2015; 612 Mor,A. 
2013}} However, the choice that patients and clinicians face is not between RBS and PBS 
but between RBS and medical management in patients who have already undergone LAGB. 
Patients requiring RBS are different to those undergoing PBS; they have by definition failed a 
primary bariatric surgical intervention for a variety of reasons which might put them at higher 
risk for a further revisional procedure. Therefore direct comparison of RBS with PBS is not 
necessarily of great relevance.  
In addition, while the impact of PBS on obesity-related comorbidities is well established, the 
impact of RBS on these comorbidities is far less certain{{499 Aftab,H. 2014; 500 
Kanoupakis,E. 2001; 501 Sarkhosh,K. 2013; 498 Sovik,T.T. 2011; 497 Sjostrom,L. 2004}}  
Obesity has a negative impact upon quality of life (QOL){{627 Kushner,R.F. 2000}} and 
there is increasing evidence that QOL can be improved significantly following bariatric 
surgery.{{623 Driscoll,S. 2016; 624 Major,P. 2015; 625 Andersen,J.R. 2015; 626 Hachem,A. 
2016}} It is tempting to extrapolate the positive impact that PBS has been shown to have on 
QOL and hypothesise that RBS, if achieving similar levels of weight loss and comorbidity 
improvement should result in similar QOL improvements. However, patients undergoing 
RBS are likely to have different characteristics to patients receiving bariatric surgery for the 
first time. It is possible that some of those physical, psychological or social factors have 
contributed to the failure of their initial LAGB and therefore may be more resistant to 
treatment. Indeed, there is much evidence to suggest that psychological and social factors, 
both preoperative and postoperatively, are predictive of poorer outcomes following bariatric 
surgery.{{556 Gordon,P.C. 2014; 561 Kalarchian,M.A. 2008; 552 Livhits,M. 2012; 553 van 
Hout,G.C. 2005; 554 Wedin,S. 2014; 555 Wimmelmann,C.L. 2014}} 
Hence, we aimed to conduct a systematic review and meta-analysis of observational and 
interventional studies to evaluate the efficacy and safety of revisional bariatric surgery 
(RYGB and SG) following a failed LAGB in regards to complication rates, weight loss, 
resolution of obesity-related comorbidities and QOL.
 Methods 
A systematic review and meta-analysis was performed. This was performed using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
recommendations.{{239 Moher,D. 2010}} 
Eligibility Criteria 
English language, prospective and retrospective, observational and interventional studies 
were included. Studies were included if they: 1. Included patients who had undergone PBS in 
the form of a gastric band and who subsequently underwent RBS: either a gastric band 
converted to RYGB (B-RYGB) or a gastric band converted to SG (B-SG); 2. Presented data 
on one or more of the following postoperatively: weight change at a minimum of six months; 
obesity-related comorbidities at any time point; or quality of life data at any time point; 3. 
Included more than 10 patients.  Studies including patients undergoing other types of 
revisional procedure (eg. revisions of vertical banded gastroplasty, revisions of sleeve 
gastrectomy or gastric band revisions not in the form of either B-RYGB or B-SG) were 
excluded unless the data regarding B-RYGB and B-SG was clearly separable from other data. 
Other exclusions included studies reporting on data from less than 10 patients and studies 
reporting data from open revisional procedures.  
Information sources and search strategy 
A literature search was performed using Medline, Embase, The Cochrane Library and NHS 
Evidence up to November 2015. The search was performed using combinations of keywords: 
laparoscopic adjustable gastric banding; laparoscopic sleeve gastrectomy; laparoscopic roux-
en-y gastric bypass; revision; revisional; reoperation; salvage; rescue; repeat; weight loss; 
postoperative complication; surgical complication; morbidity; mortality; quality of life; 
comorbidities. The exact search strategy can be seen in Appendix 1. In addition to the above 
databases, the reference lists of included studies were also searched manually for additional 
studies. 
Study selection    
Studies identified by the search strategy above were screened for inclusion using a two-step 
process. Firstly, the titles and abstracts of each study were assessed (AS and VC), if these 
were felt to be relevant then the full text or the paper was accessed. Secondly, the full text 
was assessed for the inclusion and exclusion criteria listed above (AS and VC). Differences 
between the assessors were resolved by discussion and mutual agreement.   
Data collection 
Data collected included: study design; the inclusion and exclusion criteria of each study; 
sample size; demographic data; pre and postoperative body mass index (BMI) and/or weight; 
length of hospital stay (LOS); operative time; postoperative morbidity and mortality; length 
of follow-up; %EWL; comorbidity resolution or improvement; QOL data. 
Where %EWL was not explicitly stated, this was, where possible, calculated using the 
formula: postoperative weight loss / (preoperative weight-ideal body weight). The weight at 
which a BMI of 25 would be obtained was used as the ideal body weight.{{652 Deitel,M. 
2007}} 
Summary measures and synthesis of results 
Stats Direct version 3.0.141 (StatsDirect Ltd., Altrincham, UK) was used to analyse data. 
Mean values for follow-up, operation time and LOS were combined and expressed using 
weighted means. Meta-analysis of effect size, Forest plots, relative risk and pooled 
prevalence data were calculated using the Dersimonian-Laird random effects model.{{240 
DerSimonian,R. 1986}} A p-value of less than 0.05 was considered statistically significant. 
Heterogeneity was expressed using I
2
, where values of 25%, 50%, and 75% correspond to cut 
off points for low, moderate, and high degrees of heterogeneity.{{633 Higgins,J.P. 2003}} 
  
Results 
Study selection 
The literature search produced 358 results. Figure 1 shows the PRISMA flow diagram 
detailing the process of study selection.  Ultimately the process produced 36 studies which 
were included in the final analysis.{{416 Aarts,E. 2014; 587 Abu-Gazala,S. 2012; 463 
Acholonu,E. 2009; 438 Alqahtani,A.R. 2013}}{{420 Carandina,S. 2014; 417 Carr,W.R. 
2015; 430 Delko,T. 2014; 419 Emous,M. 2015}}{{464 Frezza,E.E. 2009; 447 Goitein,D. 
2011; 418 Gonzalez-Heredia,R. 2015; 443 Hii,M.W. 2012}}{{451 Jacobs,M. 2011; 437 
Jennings,N.A. 2013; 440 Kafri,N. 2013; 436 Khoursheed,M. 2013}}{{537 Langer,F.B. 2008; 
433 Liu,K.H. 2013; 427 Marin-Perez,P. 2014; 585 Mognol,P. 2004; 435 Moon,R.C. 
2013}}{{586 Moore,R. 2009; 474 Muller,M.K. 2008; 421 Noel,P. 2014; 434 Perathoner,A. 
2013}}{{588 Rebibo,L. 2012; 446 Robert,M. 2011}}{{428 Silecchia,G. 2014; 441 
Slegtenhorst,B.R. 2013; 475 Spivak,H. 2007}}{{465 Topart,P. 2009; 472 Topart,P. 2007; 
432 Tran,T.T. 2013; 584 Weber,M. 2003}}{{439 Yazbek,T. 2013; 411 Yeung,L. 2015}} 
Study characteristics 
Table 1 describes the study designs and population characteristics of the included studies. 
Out of 36 studies, eight studies{{587 Abu-Gazala,S. 2012; 417 Carr,W.R. 2015; 435 
Moon,R.C. 2013; 427 Marin-Perez,P. 2014; 420 Carandina,S. 2014; 411 Yeung,L. 2015; 436 
Khoursheed,M. 2013; 418 Gonzalez-Heredia,R. 2015}} reported patients undergoing B-
RYGB and B-SG separately. In total therefore there were 44 data sets. The 36 studies 
included a total sample of 2617 patients (2144 female, 415 male, two studies did not 
state{{418 Gonzalez-Heredia,R. 2015; 474 Muller,M.K. 2008}}). The smallest study 
included 10 patients (as per the inclusion criteria){{464 Frezza,E.E. 2009}} whilst the largest 
included 300 patients.{{421 Noel,P. 2014}} Twenty-six studies were retrospective and 10 
were prospective studies. No controlled or randomised studies were identified. The earliest 
study was published in 2003,{{584 Weber,M. 2003}} while 61.0% (22 out of 36) were 
published in the last five years. 
Most revisional procedures were B-RYGB (n=1583, 60.5%) while the remaining were B-SG 
(n=1034, 39.5%). Women made up 83.8% (2144 of 2559) of the overall study population and 
the weighted mean age was 42.7. Further demographic data can be seen in Table 2.  
A one-stage procedure involves removal of the gastric band concomitantly with performance 
of RBS whereas with a two-stage procedure the band is removed and RBS performed at a 
subsequent date. In ten studies all patients underwent a one-stage conversion and in three 
studies all patients underwent a two-stage conversion. Nineteen studies included patients 
undergoing a mixture of one and two-stage procedures. Four studies did not specify whether 
the procedures were one or two-stage. In the 32 studies where this data was available 79.7% 
(1117 of 1402) of RYGBs and 47.2% (412 of 873) of SGs were performed as one-stage 
procedures (p<0.0001).  
Twenty-eight 28 studies (2300 patients) reported their indications for revision (Table 3). The 
most common indication for revision was insufficient weight loss. Most studies defined this 
as %EWL less than 25%, however a number of studies did not provide a definition. 
Twenty-four studies reported their mean length of follow-up.  Weighted mean follow-up was 
27.1 +/-10.0 months. 
Synthesis of results 
Mortality and Morbidity 
Thirty-four studies reported on mortality and only one death within 30 days was reported 
(0.0004%). Morbidity and postoperative complications were reported by 33 studies. The 
overall pooled incidence of complications was 13.2% (95% CI: 9.5-17.3%, I
2
=87.1%, 32 
studies). Seventeen studies broke complications down into early (less than 30 days) and late 
(greater than 30 days). The pooled early incidence of complications was 8.9% (95% CI: 6.5-
11.7%, I
2
=56.6%) and the pooled late incidence of complications was 8.1% (95% CI: 4.4-
12.8%, I
2
=85.5%). Anastomotic or staple line leak was reported in 2.0% (95% CI: 1.5-2.7%, 
I
2
=13.2%, 33 studies) and return to theatre in 5.4% (95% CI: 3.4-7.8%, I
2
=73.7%, 24 
studies).  The conversion rate to an open procedure was 1.2% (95% CI: 0.7-1.9%, I
2
=31.1%). 
Results for separate pooled analysis of studies reporting RYGB and SG can be found in table 
6. 
A number of studies compared morbidity between groups undergoing B-RYGB and B-SG. 
Meta-analysis of these studies demonstrates that there was no difference between the groups 
in overall morbidity (RR 1.69, 95%CI: 0.95-3.01, p=0.07, 6 studies{{436 Khoursheed,M. 
2013; 427 Marin-Perez,P. 2014; 411 Yeung,L. 2015; 587 Abu-Gazala,S. 2012; 420 
Carandina,S. 2014; 418 Gonzalez-Heredia,R. 2015}}), leak rate (RR 1.43, 95% CI: 0.46-
4.46, p=0.54, 7 studies{{418 Gonzalez-Heredia,R. 2015; 436 Khoursheed,M. 2013; 587 Abu-
Gazala,S. 2012; 420 Carandina,S. 2014; 417 Carr,W.R. 2015; 411 Yeung,L. 2015; 427 
Marin-Perez,P. 2014}}) or return to theatre (RR 2.79, 95% CI: 0.80-9.80, p=0.11, 4 
studies{{587 Abu-Gazala,S. 2012; 417 Carr,W.R. 2015; 436 Khoursheed,M. 2013; 411 
Yeung,L. 2015}}). 
None of the studies directly compared morbidity rates between one and two-stage RBS. 
Pooling of the morbidity from the studies that did not mix one and two-stage procedures 
suggests overall morbidity for RYGB was 10.0% (95% CI: 5.7-15.2%, I
2
=26.8%, 4 studies) 
and 16.2% (1 studies) in the one and two-stage groups respectively. For SG the overall 
morbidity was 7.3% (95% CI: 3.2-12.9%, I
2
=60.3%, 6 studies) and 6.6% (95% CI: 0.5-
19.1%, I
2
=89.9%, 3 studies) in the one and two-stage groups respectively. 
Operation Time 
Twenty-six studies reported mean operative time. The weighted mean operative time was 
higher for B-RYGB than B-SG (152.8 +/-41.0 minutes vs 125.0 +/-16.1 minutes, p<0.01).  
Length of stay 
Twenty studies reported mean LOS. The weighted mean LOS was longer for B-RYGB 
patients than B-SG (5.2 +/-1.9 days vs 4.1 +/-1.5 days, p<0.01). 
Weight loss 
Weight loss outcomes for all studies can be found in Table 7. Different studies used different 
weight loss outcome measures. The majority of studies (30 of 36) reported %EWL with 
various lengths of follow-up. %EWL for all patients combined at 6, 12 and 24 months was 
44.5% (95% CI: 41.0-48.0%), 55.7% (95% CI: 52.7-58.7%) and 59.7% (95% CI: 55.6-
63.8%) respectively (Table 8). Tables 9 and 10 show the %EWL following B-RYGB and B-
SG. A number of studies directly compared %EWL between patients undergoing B-RYGB 
and those undergoing B-SG. There was no statistical difference in %EWL between these two 
groups of patients at 6 months (3 studies{{420 Carandina,S. 2014; 418 Gonzalez-Heredia,R. 
2015; 436 Khoursheed,M. 2013}}: d=-0.17, p=0.67), 12 months (7 studies{{436 
Khoursheed,M. 2013; 427 Marin-Perez,P. 2014; 435 Moon,R.C. 2013; 587 Abu-Gazala,S. 
2012; 420 Carandina,S. 2014; 417 Carr,W.R. 2015; 418 Gonzalez-Heredia,R. 2015}}: 
d=0.11, p=0.63) and 24 months (4 studies{{420 Carandina,S. 2014; 417 Carr,W.R. 2015; 427 
Marin-Perez,P. 2014; 435 Moon,R.C. 2013}}: d=0.37, p=0.24) (Figure 2). 
A number of studies analysed the mean reduction in BMI. Weighted mean BMI decrease at 6, 
12 and 24 months was 10.9 +/-2.5 (five studies{{584 Weber,M. 2003; 475 Spivak,H. 2007; 
585 Mognol,P. 2004; 437 Jennings,N.A. 2013; 463 Acholonu,E. 2009}}, 11.2 +/-3.1 (five 
studies{{437 Jennings,N.A. 2013; 585 Mognol,P. 2004; 584 Weber,M. 2003; 441 
Slegtenhorst,B.R. 2013; 430 Delko,T. 2014}}) and 11.5 +/-5.3 (three studies{{430 Delko,T. 
2014; 437 Jennings,N.A. 2013; 446 Robert,M. 2011}}) respectively.  
Eleven studies compared BMI before LAGB as well as before and after RBS. The mean BMI 
prior to LAGB in these studies was 46.4 (95% CI: 45.5-47.4), prior to RBS was 43.7 (95% 
CI: 42.4-44.9) and a mean of 17.2 (95% CI: 12.6-21.8) months after RBS was 33.5 (95% CI: 
32.5-34.5). Therefore RBS contributed 78.8% (95% CI: 70.5-87.1%) of their total weight 
loss.  
Comorbidity Outcomes 
Definitions of what exactly constituted remission or improvement of a comorbidity varied 
between studies. For diabetes and hypertension, all studies defined remission as the cessation 
of medications and improvement as the reduction in dose or number of medications. 
However, whereas Moon et al{{435 Moon,R.C. 2013}} required patients to achieve a fasting 
glucose level of <125mg/dl or a blood pressure of <140/90mmHg for diabetes and 
hypertension respectively, other studies did not specify this. Robert et al{{446 Robert,M. 
2011}} simply required a normal HbA1C or blood pressure to be reached with no definition 
of what values they consider normal. The other studies{{441 Slegtenhorst,B.R. 2013; 439 
Yazbek,T. 2013; 411 Yeung,L. 2015}} classified patients purely on the basis of their 
medications. Robert el al{{446 Robert,M. 2011}} considered obstructive sleep apnea (OSA) 
to be in remission if patients achieved an apnea-hypopnea index (AHI) of <15. They 
considered improvement to be an AHI <30. Yazbek et al{{439 Yazbek,T. 2013}} classified 
remission as a cessation of the use of continuous positive airway pressure (CPAP). 
Comorbidity outcomes for individual studies can be seen in Table 11. Five studies reported 
remission rates in patients with diabetes prior to their revisional procedure.{{411 Yeung,L. 
2015; 441 Slegtenhorst,B.R. 2013; 446 Robert,M. 2011; 435 Moon,R.C. 2013; 439 
Yazbek,T. 2013}} The pooled remission rate was 46.5% (95% CI: 21.2-72.9%, I
2
=83.5) 
among the 79 (pooled incidence of diabetes in these five studies was 19.9%, 95% CI: 14.9-
25.6%) patients with diabetes studied. Three studies reported that 84.0% (95% CI: 51.5-
99.7%, I
2
=84.7%) of 52 (pooled incidence of diabetes = 21.4%, 95% CI: 13.0-31.1%) 
patients achieved either remission or improvement.{{411 Yeung,L. 2015; 435 Moon,R.C. 
2013; 446 Robert,M. 2011}} 
Of five studies, looking at 150 (pooled incidence of hypertension = 37.2%, 95% CI: 30.9-
43.9%) patients with hypertension, four reported on remission{{439 Yazbek,T. 2013; 411 
Yeung,L. 2015; 441 Slegtenhorst,B.R. 2013; 435 Moon,R.C. 2013}}. Of these, 35.9% (95% 
CI: 23.1-49.8%, I
2
=57.8%) were considered to be in remission following revisional surgery. 
Three studies reported on remission or improvement and reported 71.6% (95% CI: 54.5-
86.0%, I
2
=67.6%) of patients achieved either remission or an improvement in their 
hypertension.{{435 Moon,R.C. 2013; 446 Robert,M. 2011; 411 Yeung,L. 2015}}  
Only two studies reported improvement of OSA, demonstrating that 80.8% (95% CI: 65.0-
92.6%, I
2
=0.0%) of patients improved or were cured.{{439 Yazbek,T. 2013; 446 Robert,M. 
2011}} 
Quality of life  
Only two studies looked at QOL outcomes.{{446 Robert,M. 2011; 440 Kafri,N. 2013}} 
Kafri et al{{440 Kafri,N. 2013}} reported the extent to which patients agreed with four 
statements. They did not use a validated QOL measure. The study demonstrated that 73% of 
patients reported being happier, 63% reported feeling more attractive and 70% reported being 
satisfied with their appearance after their revisional surgery. However, only 22% were 
satisfied with the extent of their weight loss. Robert et al{{446 Robert,M. 2011}} used the 
BAROS questionnaire{{566 Oria,H.E. 1998}} to assess QOL. They reported a mean 1.5 
point gain in QOL following revisional surgery. 
  
Discussion 
Revisional bariatric surgery is on the rise due to the rapid increase in patients undergoing 
bariatric surgery. Unfortunately, there is a relative lack of evidence to support the practice. 
Unlike PBS, for which there are now well conducted longitudinal and randomised controlled 
trials (RCTs), our systematic review shows that the evidence for RBS is limited with no 
RCTs and many retrospective studies.{{616 Buchwald,H. 2004; 619 Christou,N.V. 2004; 
593 Colquitt,J.L. 2014; 617 Picot,J. 2009; 620 Sjostrom,L. 2007}}  
The results of this systematic review suggest that both B-RYGB and B-SG are viable options 
for patients after failed LAGB. The pooled morbidity and mortality rates described in this 
systematic review are comparable to those reported for PBS and do not suggest that RBS is 
associated with a significant increase in morbidity rates.{{609 Mahawar,K.K. 2015}} 
Anastomotic or staple line leaks are the most feared complication following RBS. However 
the pooled leak rate of 2.2% after B-SG is similar to that described by Aurora et al in their 
systematic review of leak rates after primary SG.{{643 Aurora,A.R. 2012}} Similarly, a leak 
rate of 1.8% after B-RYGB is similar to that reported for primary RYGB.{{609 
Mahawar,K.K. 2015; 644 Morales,M.P. 2011}} Some authors have suggested that 
complication rates, particularly leak rates, may be higher after B-SG than after B-
RYGB.{{463 Acholonu,E. 2009; 629 Coblijn,U.K. 2013}} However, this has not been seen 
in our results. 
Our data suggests that surgeons are more hesitant about performing one-stage B-SG than B-
RYGB. B-RYGB was significantly more likely to be performed in a single stage than B-SG 
in our analysis. This is potentially influenced by the fear of increased leak rates in B-SG as 
discussed above. The limited data we are able to present would suggest that one-stage 
procedures are not associated with higher morbidity.  
Overall, these findings suggest that patients should expect a %EWL of 44.5%, 55.7% and 
59.7% at 6, 12 and 24 months respectively. A number of systematic reviews analysing weight 
loss after PBS have reported %EWL of 61-70%.{{616 Buchwald,H. 2004; 621 Chang,S.H. 
2014; 622 Garb,J. 2009}} However, such direct comparisons lack relevance due to the 
differences in the study populations. Nonetheless, the %EWL observed in this systematic 
review is clinically relevant and would have a significant impact on obesity related 
comorbidities.{{637 Magkos,F. 2016; 638 Wing,R.R. 2011}} It should be emphasised again 
that the choice facing patients and clinicians is not between PBS and RBS but between RBS 
and medical management. There does not appear to be a difference in %EWL outcomes 
between B-RYGB and B-SG but the number of studies is small and further research to assess 
which procedure is most effective is needed. 
This systematic review shows that there is a paucity of evidence regarding the impact of RBS 
on obesity related comorbidities. A small number of studies showed that a significant 
proportion of patients will notice an improvement in their diabetes, hypertension and OSA 
(84.0%, 71.6% and 80.8% respectively), which is similar to that reported following 
PBS.{{616 Buchwald,H. 2004; 621 Chang,S.H. 2014}} Although these results are 
promising, further studies are needed to assess and quantify the benefits that patients are able 
to achieve in their medical comorbidities following RBS.  
Our study identified only two studies which looked at QOL outcomes following RBS. Of 
these only one{{446 Robert,M. 2011}} used a validated QOL assessment tool (the BAROS 
questionnaire). Their results did suggest an improvement in QOL after revisional surgery. It 
is important that QOL is assessed more rigorously in future studies. 
Although the number of LAGB procedures performed is falling, large numbers of patients are 
living with a gastric band and more are being inserted each year.{{598 Angrisani,L. 2015; 
597 Buchwald,H. 2013; 596 Buchwald,H. 2009}} Estimates suggest that 15-40% of patients 
will require revisional surgery after LAGB.{{601 Boza,C. 2011; 620 Sjostrom,L. 2007; 640 
Van Nieuwenhove,Y. 2011; 641 Himpens,J. 2011; 642 O'Brien,P.E. 2013}} Therefore it is 
likely that the number of patients with gastric bands presenting for consideration of RBS is 
likely to rise further over the next decade. It is critical therefore that high quality evidence to 
guide practice is available and although interest in this area is growing (as evidenced by the 
increased number of recent studies in this review), good quality evidence is still lacking. RBS 
is undoubtedly more technically challenging than PBS and therefore should be performed 
with caution, ideally in high volume tertiary centres.{{630 Stefanidis,D. 2013}} Although 
our results suggest that RBS can be associated with good outcomes, selection of patients for 
RBS after LAGB should still be carefully considered and take into account individual patient 
factors, preferences and reasons for failure of LAGB.  
This is not the first systematic review to focus on revisional surgery after LAGB. In 2013, 
Coblijn et al{{629 Coblijn,U.K. 2013}} systematically reviewed the data for B-RYGB or B-
SG after primary LAGB. They concentrated on postoperative morbidity rather than longer 
term weight loss and concluded that although revisional surgery was safe it did carry a higher 
complication rate than primary procedures. Elnahas et al{{608 Elnahas,A. 2013}} in 2012 
reviewed the weight loss data for patients having RBS after primary LAGB. This study 
predates the majority of studies included in our review and the number of patients included 
was much smaller. The mean %EWL they describe is similar to our findings for B-RYGB, 
however they describe a %EWL of only 22% for B-SG. In contrast, our findings do not 
suggest a difference, at least in the short term, in %EWL between B-RYGB and B-SG. Most 
recently, Mahawar et al{{609 Mahawar,K.K. 2015}} performed a systematic review 
comparing revisional RYGB and SG to their respective primary procedures. Whilst they did 
not restrict themselves purely to revisions following LAGB, the majority of patients had 
undergone LAGB as their primary procedure. They concluded that RBS carried a higher 
complication rate than PBS. Although they did not perform meta-analysis on the weight loss 
data, they found that the majority of included studies reported inferior weight loss for RBS 
than PBS. Our study, is more recent and therefore includes significantly more patients. In 
addition, none of the previous systematic reviews include data on comorbidity resolution and 
QOL in the analysis.  
Our study has several limitations. The quality of any systematic review is limited by the 
quality of the included studies. None of the included studies were RCTs, all were 
observational studies of variable size, design and quality. Length of follow-up, outcome 
measures, surgical techniques and inclusion criteria all varied widely between studies. 
Although the overall number of patients was relatively large (2617), the wide variety of 
outcome measures analysed by the different studies means that for each outcome the number 
of patients available for analysis was often small. The relatively recent enthusiasm for RBS 
naturally limits the availability of long-term follow up and most of the studies include only 
relatively short term results.  
Conclusions 
This study shows that the evidence for RBS, though limited and lacking in RCTs, suggests 
that RBS results in significant weight loss, obesity-related comorbidity resolution and has a 
positive impact on QOL, with an acceptable safety profile. Further, high quality studies, 
particularly RCTs are required to assess long-term efficacy and safety of RBS.  
  
Tables 
Table 1 – Design and population characteristics of included studies 
 Year Country Setting Design 
Revisional 
procedure 
Number Exclusions 
% 
Female 
Age 
Preoperative 
BMI 
Follow 
up 
(months) 
Weber{{584 
Weber,M. 2003}} 
2003 Switzerland 
Single-
centre 
Prospective RYGB 32  71.9 46.0 42.0 10.5 
Mognol{{585 
Mognol,P. 2004}} 
2004 France 
Single-
centre 
Retrospective RYGB 70  72.5 41.0 44.9 7.3 
Muller{{474 
Muller,M.K. 
2008}} 
2007 Switzerland 
Single-
centre 
Prospective RYGB 30    41.9  
Spivak{{475 
Spivak,H. 2007}} 
2007 USA 
Single-
centre 
Prospective RYGB 33  90.9 43.8 42.8 15.7 
Topart{{472 
Topart,P. 2007}} 
2007 France 
Single-
centre 
Retrospective RYGB 32  90.6 40.9 43.1  
Langer{{537 
Langer,F.B. 
2008}} 
2008 Austria 
Single-
centre 
Retrospective RYGB 25 Band complications 96.0 38.0 47.6  
Acholonu{{463 
Acholonu,E. 
2009}} 
2009 USA 
Single-
centre 
Retrospective SG 15  80.0 46.6 38.7 6.0 
Frezza{{464 
Frezza,E.E. 
2009}} 
2009 USA 
Single-
centre 
Retrospective SG 10  60.0 50*  19.0 
Moore{{586 
Moore,R. 2009}} 
2009 USA 
Single-
centre 
Retrospective RYGB 26  88.5 46.0 40.0 18.0 
Topart{{465 
Topart,P. 2009}} 
2009 France 
Single-
centre 
Retrospective RYGB 58  91.4 42.5 43.2  
Goitein{{447 
Goitein,D. 2011}} 
2011 Israel 
Single-
centre 
Retrospective SG 46  73.9 40 43.1 17.0 
Abu-Gazala{{587 
Abu-Gazala,S. 
2012}} 
2012 Israel 
Single-
centre 
Retrospective RYGB 18  55.6 43.7 41.6 14.6 
 
 
    SG 18  77.8 38.6 40 14.0 
Jacobs{{451 
Jacobs,M. 2011}} 
2011 USA 
Single-
centre 
Retrospective SG 32  78.1 45.4 42.7 26.0 
Robert{{446 
Robert,M. 2011}} 
2011 France 
Multi-
centre 
Retrospective RYGB 85  84.7 39.3 42.9 22.0 
Hii{{443 
Hii,M.W. 2012}} 
2012 Australia 
Single-
centre 
Prospective RYGB 82  85.4 49* 43.0  
Kafri{{440 
Kafri,N. 2013}} 
2013 Israel 
Single-
centre 
Prospective SG 12  100 48.8 37.9 17.0 
Rebibo{{588 
Rebibo,L. 2012}} 
2012 France 
Single-
centre 
Retrospective SG 46  93.5 42.0 44.0  
Alqahtani{{438 
Alqahtani,A.R. 
2013}} 
2013 
Saudi 
Arabia 
Single-
centre 
Retrospective SG 56  71.4 33.5 44.4 24.0 
Jennings{{437 
Jennings,N.A. 
2013}} 
2013 UK 
Single-
centre 
Prospective RYGB 55  81.8 46.3 49.7 24.0 
Khourshead{{436 
Khoursheed,M. 
2013}} 
2013 Kuwait 
Single-
centre 
Retrospective SG 42  85.7 35.6 38.5* 9.8 
 
 
    RYGB 53  86.8 39.0 43.2* 29.3 
Liu{{433 
Liu,K.H. 2013}} 
2013 France 
Single-
centre 
Retrospective RYGB/SG 88  84.1 42.8 44.7 35.6 
Moon{{435 
Moon,R.C. 
2013}} 
2013 USA 
Single-
centre 
Retrospective RYGB 41  90.2 43.7 41.8  
 
 
    SG 13  92.3 40.8 39.0  
Perathoner{{434 
Perathoner,A. 
2013}} 
2013 Australia 
Single-
centre 
Retrospective RYGB 108  85.2 46* 37.9* 40.8 
Slegtenhorst{{441 
Slegtenhorst,B.R. 
2013}} 
2013 Netherlands 
Single-
centre 
Retrospective RYGB 66  87.9 42.0 46.2 12.0 
Tran{{432 
Tran,T.T. 2013}} 
2013 USA 
Single-
centre 
Retrospective RYGB/SG 61  91.8 43.7 42.9 12.4 
Yazbek{{439 
Yazbek,T. 2013}} 
2013 Canada 
Single-
centre 
Retrospective SG 90  85.6 41.0 42.0 24.0 
Aarts{{416 
Aarts,E. 2014}} 
2014 Netherlands 
Single-
centre 
Retrospective RYGB 195 
Band complications 
Band in place less 
than 1 year 
82.1 43.0 41.0 40.0 
Carandina{{420 
Carandina,S. 
2014}} 
2014 France 
Single-
centre 
Retrospective RYGB 74  93.2 42.1 45.6 29.1 
 
 
    SG 34  91.2 42.4 47.5 24.2 
Delko{{430 
Delko,T. 2014}} 
2014 Switzerland 
Single-
centre 
Prospective RYGB 48  75.0 43.5 41.9  
Gonzalez-
Heredia{{418 
Gonzalez-
Heredia,R. 
2015}} 
2015 USA 
Single-
centre 
Retrospective SG 26   38.6 48.6  
 
 
    RYGB 12   33.9 44.6  
Marin-
Perez{{427 
Marin-Perez,P. 
2014}} 
2014 USA 
Single-
centre 
Prospective RYGB 39  84.6 49.0 42.0 22.0 
  
    SG 20  75.0 44.0 39.0 33.0 
Noel{{421 Noel,P. 
2014}} 
2014 France 
Single-
centre 
Retrospective SG 300  87.0 43.3 43.0 35.0 
Silecchia{{428 
Silecchia,G. 
2014}} 
2014 Italy 
Multi-
centre 
Retrospective SG 76  78.9 45.5* 43.9*  
Carr{{417 
Carr,W.R. 2015}} 
2015 UK 
Single-
centre 
Prospective RYGB 64  79.7 47.7 49.5  
 
 
    SG 25  68.0 49.8 52.7  
Emous{{419 
Emous,M. 2015}} 
2015 Netherlands 
Single-
centre 
Prospective RYGB 257  82.9 43*  29.0 
Yeung{{411 
Yeung,L. 2015}} 
2015 USA 
Single-
centre 
Retrospective RYGB 32  81.3 51.0 41.4  
 
 
    SG 72  84.7 45.0 39.6  
Where cells are empty data was not available 
Table 2 – Basic population demographics of patients included in the systematic review 
 Data sets Patients Number of patients (%) 
Male 41 2559 415 (16.2) 
Female 41 2559 2144 (83.8) 
RYGB 44 2617 1583 (60.5) 
SG 44 2617 1034 (39.5) 
Age 38 2054 42.7 (41.6-43.7) 
Time to revision (months) 28 1457 49.7 (42.4-57.1) 
BMI (before LAGB) 19 982 46.5 (45.7-47.4) 
BMI (before revision) 38 2071 43.4 (42.5-44.3) 
One stage 29 2034 1223 (60.1) 
Two stage 29 2034 811 (39.9) 
Diabetes 14 742 142 (19.1) 
Hypertension 13 694 210 (30.3) 
Obstructive sleep apnoea 8 479 80 (16.7) 
Dyslipaemia 6 371 77 (20.8) 
 Table 3 – Indications for revisional procedure 
Indication Number (%) 
Weight regain 251 (10.9) 
Insufficient weight loss 1079 (46.9) 
Slippage 265 (11.5) 
Erosion 36 (1.6) 
Pouch/oesophageal dilatation 255 (11.1) 
Band 
intolerance/dysphagia/reflux 
329 (14.3) 
Infection 18 (0.8) 
Tubing complications 42 (1.8) 
Other 25 (1.1) 
 
Table 4 – Operative times, length of stay and postoperative morbidity described in included 
studies 
 Number 
Revisional 
procedure 
One 
stage 
Two 
stage 
Mean Op 
time (mins) 
LOS days 
Mean 
LOS 
median 
Mortality Morbidity Leak 
Return to 
theatre 
Weber{{584 
Weber,M. 
2003}} 
32 RYGB   215 8.9  0 
4 Early 
 
2 Late 
1 
2 Early 
 
2 Late 
Mognol{{58
5 Mognol,P. 
2004}} 
70 RYGB 47 23  7.2  0 
10 Early 
 
6 Late 
0 
4 Early 
 
0 Late 
Muller{{474 
Muller,M.K
. 2008}} 
30 RYGB      0 
Early not 
described 
 
2 Late 
0 
Early not 
described 
 
6 Late 
Spivak{{475 
Spivak,H. 
2007}} 
33 RYGB 33 0 105 2.8  0 
1 Early 
 
1 Late 
0 
1 Early 
 
1 Late 
Topart{{47 32 RYGB 31 1 135   0 4 0 3 
2 Topart,P. 
2007}} 
Langer{{53
7 
Langer,F.B. 
2008}} 
25 RYGB   219 5  0 
1 Early 
 
3 Late 
0  
Acholonu{{
463 
Acholonu,E. 
2009}} 
15 SG 13 2 120 5.5  0 
2 Early 
 
Late not 
described 
1 1 
Frezza{{464 
Frezza,E.E. 
2009}} 
10 SG   87   0 0 0 0 
Moore{{586 
Moore,R. 
2009}} 
26 RYGB 24 2 160 3  0 2 1 1 
Topart{{46
5 Topart,P. 
2009}} 
58 RYGB 50 8 128 7.7  0 5 0 3 
Goitein{{44
7 Goitein,D. 
2011}} 
46 SG 26 20 117 3  0 
3 Early 
 
Late not 
described 
2 
2 Early 
 
Late not 
described 
Abu-
Gazala{{58
7 Abu-
Gazala,S. 
2012}} 
 
 
18 RYGB   195 3.9  0 1 0 0 
18 SG   111 4.3  0 2 1 1 
Jacobs{{451 
Jacobs,M. 
2011}} 
32 SG 32 0    0 0 0 0 
Robert{{44
6 Robert,M. 
2011}} 
85 RYGB 71 14 166 5.2 4 0 
6 Early 
 
4 Late 
0 
2 Early 
 
1 Late 
Hii{{443 
Hii,M.W. 
2012}} 
82 RYGB 64 18 132  4.5 0 38 1 10 
Kafri{{440 
Kafri,N. 
2013}} 
12 SG 12 0    0    
Rebibo{{58
8 Rebibo,L. 
2012}} 
46 SG   138 5.8  0 4 2 3 
Alqahtani{{
438 
Alqahtani,A
.R. 2013}} 
56 SG   129 2.6  0 
2 Early 
 
O Late 
0 0 
Jennings{{4
37 
Jennings,N.
A. 2013}} 
55 RYGB 43 12   3     
Khourshead
{{436 
Khoursheed
,M. 2013}} 
 
 
42 SG   108  2 0 3 0 0 
53 RYGB   161  3 0 11 1 2 
Liu{{433 
Liu,K.H. 
2013}} 
88 RYGB/SG 29 59    0 
1 Early 
 
10 Late 
1  
Moon{{435 
Moon,R.C. 
2013}} 
 
 
41 RYGB 41 0 72 1.2      
13 SG 10 3 90 1.5      
Perathoner{
{434 
Perathoner,
A. 2013}} 
108 RYGB 56 52 197  7 0 
11 Early 
 
38 Late 
3 
9 Early 
 
18 Late 
Slegtenhors
t{{441 
Slegtenhors
t,B.R. 
2013}} 
66 RYGB 40 26  4.9  0 10 0  
Tran{{432 
Tran,T.T. 
2013}} 
61 RYGB/SG 46 15 159 2  1 
11 Early 
 
12 Late 
4 
3 Early 
 
6 Late 
Yazbek{{43
9 Yazbek,T. 
2013}} 
90 SG   112 4.2  0 13 5  
Aarts{{416 
Aarts,E. 
2014}} 
195 RYGB 195 0 112 4.5  0 14 2 8 
Carandina{
{420 
Carandina,
S. 2014}} 
 
 
74 RYGB 0 74 172 7.1  0 
10 Early 
 
2 Late 
4  
34 SG 0 34 91 6.7  0 1 Early 1  
Delko{{430 
Delko,T. 
2014}} 
48 RYGB 47 1 201   0 
9 Early 
 
11 Late 
2  
Gonzalez-
Heredia{{41
8 Gonzalez-
Heredia,R. 
2015}} 
26 SG 21 5 130 3  0 0 0  
12 RYGB 11 1  2.6  0 0 0  
  
Marin-
Perez{{427 
Marin-
Perez,P. 
2014}} 
 
 
39 RYGB   142 5  0 
1 Early 
 
8 Late 
0  
20 SG   121 4  0 
3 Early 
 
1 Late 
1  
Noel{{421 
Noel,P. 
2014}} 
300 SG 0 300 130   0 6 3 4 
Silecchia{{4
28 
Silecchia,G. 
2014}} 
76 SG 0 76    0 13 0 0 
Carr{{417 
Carr,W.R. 
2015}} 
 
 
64 RYGB 51 13    0  1 1 
25 SG 10 15    0  0 0 
Emous{{419 
Emous,M. 
2015}} 
257 RYGB 220 37    0 
12 Early 
 
9 Late 
7  
Yeung{{411 
Yeung,L. 
2015}} 
 
 
32 RYGB   224   0 
5 Early 
 
0 Late 
2 
4 Early 
 
0 Late 
72 SG   156   0 
4 Early 
 
4 Late 
1 
2 Early 
 
0 Late 
 
Table 6 – Pooled analysis of morbidity rates for RYGB and SG 
 RYGB (%) SG (%) 
Overall 
morbidity 
16.5 (11.2-22.6) I
2
 = 87.7 7.7 (4.4-11.6) I
2
 = 70.9 
Leak rate 1.8 (1.2-2.6) I
2
 = 4.6 2.2 (1.2-3.5) I
2
 = 18.7 
Return to 
theatre 
7.8 (4.9-11.3) I
2
 = 69.2 2.0 (1.0-3.4) I
2
 = 19.6 
 
Table 7 – Post operative weight loss described in included studies  
   
%EWL BMI Reduction Pre Band %EWL at 29 
months 
 Number 
Revisional 
procedure 
6 
mths 
12 
mths 
18 
mths 
24 
mths 
6 
mths 
12 
mths 
24 
mths 
36 
mths 
6 mths 12 
mths 
One 
Step 
Two 
Step 
Weber{{584 
Weber,M. 2003}} 
32 RYGB   
 
 
7.7 7.9       
Mognol{{585 
Mognol,P. 2004}} 
70 RYGB 50.0 59.0 
70.2 
 
10.4 11.0       
Muller{{474 
Muller,M.K. 
2008}} 
30 RYGB   
 
 
   6.1     
Spivak{{475 
Spivak,H. 2007}} 
33 RYGB   
 
 
8.9        
Topart{{472 
Topart,P. 2007}} 
32 RYGB  58.8 
 
 
        
Langer{{537 
Langer,F.B. 
2008}} 
25 RYGB 40.5 50.8 
 
 
    48.5 56.9   
Acholonu{{463 
Acholonu,E. 
2009}} 
15 SG 64.2  
 
 
14.3        
Frezza{{464 
Frezza,E.E. 
2009}} 
10 SG   
20.0 
 
        
Moore{{586 
Moore,R. 2009}} 
26 RYGB   
 
 
    51.0 56.0   
Topart{{465 
Topart,P. 2009}} 
58 RYGB  66.1 
 
 
        
Goitein{{447 
Goitein,D. 2011}} 
46 SG 37.0 53.0 
 
51.0 
        
Abu-Gazala{{587 
Abu-Gazala,S. 
2012}} 
 
 
18 RYGB  52.0           
18 SG  69.7 
 
 
        
Jacobs{{451 
Jacobs,M. 2011}} 
32 SG   
 
60.0 
        
Robert{{446 
Robert,M. 2011}} 
85 RYGB   
 
 
  8.1      
Hii{{443 
Hii,M.W. 2012}} 
82 RYGB 43.0 50.0 
54.0 
55.0 
        
Kafri{{440 
Kafri,N. 2013}} 
12 SG   
44.3 
 
        
Rebibo{{588 
Rebibo,L. 2012}} 
46 SG 28.8 47.4 
 
53.1 
        
Alqahtani{{438 
Alqahtani,A.R. 
56 SG 48.4 66.4 
 
80.1 
        
2013}} 
Jennings{{437 
Jennings,N.A. 
2013}} 
55 RYGB 51.6 59.5 
 
59.4 
13.6 16.3 18.1      
Khourshead{{436 
Khoursheed,M. 
2013}} 
 
 
42 SG 45.6 47.4           
53 RYGB 42.0 45.6 
 
 
        
Liu{{433 
Liu,K.H. 2013}} 
88 RYGB/SG 40.9 52.4 
 
51.7 
        
Moon{{435 
Moon,R.C. 
2013}} 
 
 
41 RYGB  57.4  62.4         
13 SG  47.7 
 
65.6 
        
Perathoner{{434 
Perathoner,A. 
2013}} 
108 RYGB  43.9 
 
 
        
Slegtenhorst{{441 
Slegtenhorst,B.R. 
2013}} 
66 RYGB  48.4 
 
 
 10.2       
Tran{{432 
Tran,T.T. 2013}} 
61 RYGB/SG 52.2 60.2 
 
66.8 
        
Yazbek{{439 
Yazbek,T. 2013}} 
90 SG 51.8 61.3 
61.6 
53.0 
        
Aarts{{416 
Aarts,E. 2014}} 
195 RYGB  60.0 
 
65.0 
        
Carandina{{420 
Carandina,S. 
2014}} 
 
 
74 RYGB 45.2 59.9  70.2         
34 SG 37.4 52.2 
 
59.9 
        
Delko{{430 
Delko,T. 2014}} 
48 RYGB  41.8 
 
45.1 
 9.2 10.1      
Gonzalez-
Heredia{{418 
Gonzalez-
Heredia,R. 
2015}} 
 
 
26 SG 53.0 64.4           
12 RYGB 36.2 46.0 
 
 
        
Marin-
Perez{{427 
Marin-Perez,P. 
2014}} 
 
 
39 RYGB  59.0  55.0         
20 SG  35.0 
 
28.0 
        
Noel{{421 Noel,P. 300 SG  64.0  64.0         
2014}} 
Silecchia{{428 
Silecchia,G. 
2014}} 
76 SG 46.5 66.4 
 
78.5 
        
Carr{{417 
Carr,W.R. 2015}} 
 
 
64 RYGB  52.1  47.9         
25 SG  44.1 
 
42.0 
        
Emous{{419 
Emous,M. 2015}} 
257 RYGB   
 
 
      53.0 67.0 
Yeung{{411 
Yeung,L. 2015}} 
 
 
32 RYGB 50.2 51.2           
72 SG 30.6 34.9 
 
 
        
 
Table 8 – Pooled %EWL for RYGB and SG 
 Studies Patients %EWL (95% CI) 
3 months 6 407 31.0 (28.0-34.0) 
6 months 16 1055 44.5 (41.0-48.0) 
12 months 26 2085 55.7 (52.7-58.7) 
18 months 5 264 59.1 (44.5-73.8) 
24 months 17 1485 60.5 (56.0-65.0) 
36 months 7 690 58.1 (48.5-67.7) 
48 months 3 393 59.9 (52.1-67.7) 
60 months 3 603 60.6 (31.8-89.4) 
 
Table 9 - Pooled %EWL for RYGB 
 Studies Patients EWL 
3 months 3 160 28.5 (23.3-33.7) 
6 months 8 403 45.9 (42.2-49.6) 
12 months 18 1072 54.2 (50.7-57.7) 
18 months 2 152 61.5 (-41.1-164.1) 
24 months 8 598 59.5 (52.6-66.4) 
36 months 4 459 60.7 (39.5-81.9) 
48 months 2 269 62.0 (20.6-103.4) 
60 months 2 303 51.3 (22.7-79.9) 
 
Table 10 - Pooled %EWL for SG 
 Studies Patients EWL 
3 months 2 98 31.3 (20.0-42.6) 
6 months 10 503 43.1 (36.2-50.0) 
12 months 14 864 57.6 (51.4-63.7) 
18 months 2 102 59.6 (-11.3-130.4) 
24 months 11 738 61.8 (54.0-69.6) 
36 months 3 170 55.4 (37.3-73.4) 
48 months 2 124 55.4 (28.2-82.6) 
 
Table 11 – Comorbidity response rates described in included studies 
 Diabetes Hypertension OSA 
Study 
Numb
er 
Procedur
e 
Patien
ts 
Follow 
up 
(mths) 
Inciden
ce 
Remissio
n 
Improvem
ent or 
remission 
Inciden
ce 
Remissio
n 
Improvem
ent or 
remission 
Inciden
ce 
Improvem
ent or 
remission 
Robert{{44
6 Robert,M. 
2011}} 
85 RYGB 85 22 26 22 26 29  17 12 10 
Moon{{435 
Moon,R.C. 
2013}} 
54 RYGB/SG 54  9 2 5 20 8 6   
Slegtenhors
t{{441 
Slegtenhors
t,B.R. 
2013}} 
66 RYGB 66 12 13 3  19 4    
Yazbek{{43
9 Yazbek,T. 
2013}} 
90 SG 90 24 14 9  32 17  17 14 
Yeung{{411 
Yeung,L. 
2015}} 
104 RYGB/SG 104  17 5 14 50 14 28   
 
  
Figures 
Figure 1: PRISMA flow diagram.{{239 Moher,D. 2010}} 
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Figure 2: Meta-analysis of studies comparing %EWL between B-RYGB and B-SG at 6, 12 
and 24 months. 
a) 6 months 
 
b) 12 months 
  
c) 24 months 
 
  
Appendix 1: Electronic Search Strategy 
A comprehensive literature search was run Medline, Embase, The Cochrane Library and 
NHS Evidence up to November 2015. The following search strategy was used: 
‘Laparoscopic Adjustable Gastric Banding OR Laparoscopic Sleeve Gastrectomy OR 
Laparoscopic Roux-en-Y Gastric Bypass’, ‘Revision OR Revisional OR Reoperation OR 
Salvage OR Rescue OR Repeat’, ‘Weight loss OR Postoperative Complication OR Surgical 
Complication OR Morbidity OR Mortality OR Quality of Life OR Comorbidities’. 
 
